Jacobs Levy Equity Management, Inc Arcus Biosciences, Inc. Transaction History

Jacobs Levy Equity Management, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$14.59 - $18.48 $344,440 - $436,275	23,608 New	23,608 $359,000
Q4 2023 Feb 14, 2024	BUY	$13.43 - $19.63 $1.66 Million - $2.43 Million	123,752 Added 88.99%	262,811 $5.02 Million
Q3 2023 Nov 16, 2023	BUY	$17.62 - $23.54 $2.45 Million - $3.27 Million	139,059 New	139,059 $2.5 Million
Q2 2020 Aug 17, 2020	SELL	$13.97 - $36.56 $310,064 - $811,449	-22,195 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$8.78 - $19.28 $496,140 - $1.09 Million	-56,508 Reduced 71.8%	22,195 $308,000
Q4 2019 Feb 14, 2020	BUY	$7.33 - $10.79 $245,965 - $362,069	33,556 Added 74.33%	78,703 $795,000
Q3 2019 Nov 14, 2019	BUY	$6.44 - $10.18 $174,337 - $275,582	27,071 Added 149.76%	45,147 $411,000
Q2 2019 Aug 13, 2019	BUY	$7.29 - $13.38 $131,774 - $241,856	18,076 New	18,076 $144,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.